VANCOUVER, British Columbia, April 27, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce that it has started discussions for the clinical trials of X-Excite in North America. The Company has endorsed the work with Omnicare of Philadelphia on the detail of the clinical trials and statistical power required.
The Company has obtained valuable information on the European clinical trials for X-Excite and will begin designing a successful trial in the United States. The work will be conducted by Omnicare, a well-respected and internationally known contract research organization (CRO). Omnicare is a U.S. based CRO with its head office in Philadelphia, PA including twenty other offices throughout the world.
"We are pleased for the advances we have been making on the development of X-Excite by engaging highly expert firms to assist us on our business development", said Dr. Hassan Salari, Global Health President & CEO.
About Sublingual Technology
The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver breakdown. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite has completed clinical development in Europe with very good results. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact: Mrs. Kelly Black Premier Media Service Inc. (480) 649-8224 kblack@premiermediaservice.com